Health2047 Announces Advisory Board Appointments
Recognized innovation experts attracted to new healthcare entity's mission to disrupt and optimize US healthcare
SAN FRANCISCO, Feb. 29, 2016 /PRNewswire/ -- Health2047, the integrated innovation company purpose-built to improve US healthcare, today announced the appointment of prominent innovation experts Norman Winarsky, Ph.D. and Karl Ronn to its newly created industry advisory board. Effective immediately, Winarsky and Ronn will help guide major innovation cycles at Health2047's rapid prototyping studio and strategically identify new high-potential market opportunities.
"Both Norman and Karl are recognized visionary leaders who bring a wealth of innovation-centric knowledge as well as entrepreneurial expertise to Health2047," said Doug Given, CEO of Health2047. "Having them on our industry advisory board accelerates Health2047's ability to drive sustainable, profitable, system-level changes that will solve big healthcare challenges by disrupting and reshaping our current healthcare system."
Winarsky has deep venture development expertise, having helped found over 30 companies in areas ranging from artificial intelligence and natural language to medical devices, robotics and nanotechnology. As past President of SRI Ventures, he built SRI's venture process from concept to marketplace – including team building, seed funding, investor identification and launch. Winarsky's passion is to help create breakthrough ventures that substantially improve the way people live and work. He was co-founder and board member of Siri, guiding the company to a successful acquisition by Apple. Winarsky currently lectures at Stanford Graduate School of Business and recently co-authored "If You Really Want to Change the World: A Guide to Creating, Building, and Sustaining Breakthrough Ventures." He was a National Science Foundation fellow, an Emmy award winner and a member of the National Academy's Committee on Forecasting Disruptive Technologies.
Ronn is a globally successful entrepreneur and advisor to CEOs and top management at Fortune 500 companies. During his 30-year tenure in management at consumer powerhouse Procter & Gamble, Ronn rose to the post of vice president of R&D and general manager of new business/healthcare; in that position, he oversaw global R&D for pharmaceuticals and over-the-counter healthcare and was responsible for developing the company's capability to create disruptive innovations. Ronn created entirely new brands that are globally revered, including Swiffer, Febreze and Mr. Clean Magic Eraser. As a result of his strategic insights and understanding of consumer behavior, these new categories rapidly grew to $1 billion in annual sales. Ronn has helped found multiple startups and continues to help Fortune 500 companies create their own billion-dollar growth engines. His book on turning disruption into business through partnerships, "The Reciprocity Advantage," has received accolades from CEOs and academics alike.
About Health2047
Integrated innovation company Health2047 Inc.—whose founding partner is the AMA—creates innovative solutions and enterprises to improve healthcare at a system level by integrating ideas, development and funding. Its studio, together with its venture and business development resources, leverages the AMA's strengths and partners with leading companies to address the biggest healthcare problems. For more information, visit www.health2047.com or follow @health2047.
SOURCE Health2047
Share this article